Psoriasis: clinical and epidemiological features and therapy issues

Cover Page
  • Authors: Bakulev A.L.1, Fitileva T.V.2, Novodezerkina E.А.2, Gilloteau I.3, Tian Н.4, Howe T.5, Pietri G.6
  • Affiliations:
    1. Saratov State Medical Universit y of the Ministr y of Healthcare of the Russian Federation
    2. Provyantskaya str., 22, Saratov, 410028
    3. Novartis Pharma AG
    4. Novartis Pharmaceuticals Co
    5. GfK Company
    6. Data Pyxis Ltd
  • Issue: Vol 94, No 3 (2018)
  • Pages: 67-76
  • Section: DRUG TREATMENT IN DERMATOVENEROLOGY
  • URL: https://vestnikdv.ru/jour/article/view/407
  • DOI: https://doi.org/10.25208/0042-4609-2018-94-3-67-76

Abstract


Aim. This study sets out to establish the demographic and clinical features of psoriasis and its co-morbidities; to describe approaches to treating patients in Russia, to whom the systemic therapy of drugs has been recommended; to assess the effects of this dermatosis on the patients' quality of life and work productivity; to assess the degree of consistency between dermatologists' and patients' estimates concerning the severity of the disease, complaints/objective manifestations and treatment satisfaction.

Methods. Data from the GfK Disease Atlas was used. This ATLAS was filed within a global programme Growth from Knowledge that collected reliable data in the context of everyday clinical practice in 9 countries. The paper presents the results solely for the Russian sample. The study involved patients with moderate or severe psoriasis who were receiving systemic therapy for this disease. Using specially developed forms, ATLAS specialists registered data about patients, their disease and received treatment. The patients affected by psoriasis, who participated in the study, were questioned about their disease. Dermatologists assessed the severity of psoriasis, the patients' complaints, co-morbidities and received treatment. The patients completed questionnaires aimed at assessing the quality of their life [Dermatology Life Quality Index, DLQI] and their work productivity [Work Productivity and Activity Impairment, WPAI]. The concordance between the patients' and the dermatologists' estimates was assessed using Cohen's kappa coefficient.

Results. Overall, 3,821 patients participated in the ATLAS programme, out of whom 300 patients were Russians. The average time since psoriasis diagnosis amounted to 9.9 years. 51 % of the patients complained about itching in the lesion areas. Psoriatic arthritis was registered in 19 % of the cases. Among co-morbidities, anxiety or depression was most often recorded (11 %, respectively). The proportion of patients with pruritus and related comorbid conditions increased with psoriasis severity. The disease negatively affected the quality of patients’ life (the average value of DLQI was 7.1) and their work productivity (a decrease in the work productivity reached 33.2 %), with these indicators deteriorating with psoriasis severity. Despite the dominance of moderate and severe psoriasis forms among the participants, 60 % of the patients received therapy only with topical medications. The concordance rate between the patients and the dermatologists concerning the estimation of psoriasis severity and treatment satisfaction was low.

Conclusion. Despite the therapy with systemic drugs, the patients' quality of life affected by severe or moderate psoriasis forms remained low. The consistency between the views on the treatment success between the patients and the dermatologists was low.


About the authors

A. L. Bakulev

Saratov State Medical Universit y of the Ministr y of Healthcare of the Russian Federation

Author for correspondence.
Email: al_ba05@mail.ru

Russian Federation

Andrey L. Bakulev — Dr. Sci. (Medicine), Prof., Department of Dermatovenereology and Cosmetology

Provyantskaya str., 22, Saratov, 410028

T. V. Fitileva

Provyantskaya str., 22, Saratov, 410028

Email: fake@neicon.ru

Russian Federation

Tat’yana V. Fitileva — Cand. Sci. (Medicine), Head of the Specialized Drugs Department

Leningradskiy prospekt, 72, bldg 3, Moscow, 125315

E. А. Novodezerkina

Provyantskaya str., 22, Saratov, 410028

Email: fake@neicon.ru

Russian Federation

Evgeniya A. Novodezerkina — Medical Advisor

Leningradskiy prospekt, 72, bldg 3, Moscow, 125315

I. Gilloteau

Novartis Pharma AG

Email: fake@neicon.ru

Switzerland

Isabel Gilloteau — Director, Department of Pharmacoeconomics, Business Section of Immunology and Dermatology

Fabrikshtrasse, 2, Basel, 4056

Н. Tian

Novartis Pharmaceuticals Co

Email: fake@neicon.ru

United States

Haijun Tian — Manager

Health Plaza, 1, East Hannover, 07936, New Jersey

T. Howe

GfK Company

Email: fake@neicon.ru

United Kingdom

Tanya Howe — Manager

Canada Square, 25, London, E14 5AB

G. Pietri

Data Pyxis Ltd

Email: fake@neicon.ru

United Kingdom

Guilhem Pietri — Manager

Arthur Avenue, 13, St. Albans, AL1 1NS, Hertfordshire

References

  1. Glickman F. S. Lepra, psora, psoriasis. J Am Acad Dermatol. 1986 May;14(5 Pt 1):863–866.
  2. Pariser D. M., Bagel J., Gelfand J. M., Korman N. J., Ritchlin C. T., Strober BE, et al. National Psoriasis Foundation Clinical Consensus on Disease Severity. Arch Dermatol. 2007;143:239–242.
  3. Global report on psoriasis. WHO 2016. Retrieved from WHO website: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf
  4. Ortonne J. P, Prinz J. C. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis. Eur J Dermatol. 2004;14(1):41–45.
  5. Sommer R., Mrowietz U., Radtke M. A., Schafer I., von Kiedrowski R., Stromer K., Enk A., Maul J. T., Reich K., Zander N., Augustin M. What is psoriasis? — Perception andassessment of psoriasis among the German population. J Dtsch Dermatol Ges. 2018;16(6):703–710.
  6. Griffiths C. E, Barker J. N. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271.
  7. Huerta C., Rivero E., Garcia Rodriguez L. A. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007;143(12):1559–1565.
  8. Sampogna F., Gisondi P., Melchi C. F., et al. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol. 2004;151(3):594–599.
  9. Yosipovitch G., Goon A., Wee J., Chan Y. H., Goh C. L. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol. 2000;143(5):969–973.
  10. Amatya B., Wennersten G., Nordlind K. Patients’ perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol. 2008;22(7):822–826.
  11. Gottlieb A. B., Chao C., Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008;19(1):5–21.
  12. Yeung H., Takeshita J., Mehta N. N., et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173–1179.
  13. Kurd S. K., Troxel A. B., Crits-Christoph P., Gelfand J. M. The risk of depression, anxiety, and suicidality in patients with psoriasis: a populationbased cohort study. Arch Dermatol. 2010;146(8):891–895.
  14. Helmick C. G., Lee-Han H., Hirsch S. C., Baird T. L., Bartlett C. L. Prevalence of psoriasis among adults in the U.S.: 2003–2006 and 2009– 2010 National Health and Nutrition Examination Surveys. Am J Prev Med. 2014;47(1):37–45.
  15. Armstrong, A. W. et al., Quality of life and work productivity impairment among psoriasis patients: Findings from the National Psoriasis Foundation survey data 2003–2011. PloS one. 2012;7(12):e52935.
  16. Reich K., Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges. 2007;5(7):566–574.
  17. Mrowietz U., Kragballe K., Reich K., et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res. 2011;303(1):1–10.
  18. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. Update 2015. EDF in cooperation with EADV and IPC. Available at: http://www.euroderm.org/edf/index.php/edf-guidelines/category/5-guidelinesmiscellaneous [Accessed on 1 Aug 2017].
  19. Finlay A. Y., Khan G. K. Dermatology Life Quality Index (DLQI) — a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210–216.
  20. Reilly M. C, Zbrozek A. S, Dukes E. M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365.
  21. Cohen J. A Coefficient of Agreement for Nominal Scales. Educational and Psychological Measurement. Educ Psychol Meas. 1960;20:37–46.
  22. Psoriasis association. 2016. Types of psoriasis. [ONLINE] Available at: https://www.psoriasis-association.org.uk [Accessed 15 February 2016].
  23. Finlay A. Y., Coles E. C. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132(2):236–244.
  24. Rapp S. R., Feldman S. R., Exum L., et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;1(3 Pt 1):401–407.
  25. Stern R. S., Nijsten T., Feldman S. R., et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136–139.
  26. Ahn C. S, Gustafson C. J., Sandoval L. F., Davis S. A., Feldman S. R. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013;14(4):315–326.
  27. Anis A. H., Bansback N., Sizto S., Gupta S. R., Willian M. K., Feldman S. R. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat. 2011;22(2):65–74.
  28. Feuerhahn J., Blome C., Radtke M. A., Augustin M. Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res. 2012;304(6):433–441.
  29. Lebwohl M. G., Bachelez H., Barker J., et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871–881.e1–30

Statistics

Views

Abstract - 1972

PDF (Russian) - 289

PlumX

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Dimensions


Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies